Motexafin lutetium

Motexafin lutetium

Names
Other names Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
Identifiers
CAS Number	246252-04-0
Jmol interactive 3D	Image
PubChem	3081907
SMILES CC([O-])=O.CCC1=C2[N-]C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=[N]([Lu+3])C5=C/2)C(C)=C\3CCCO)=C1CC
Properties
Chemical formula	C52H72LuN5O14
Molar mass	1,166.14 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is  ?)
Infobox references

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).^[1]

It is photoactivated by 732 nm light which allows greater depth of penetration.^[2]

Clinical trials

Phase II clinical trials were in progress in 1999.^[3]

A phase I trial for prostate cancer reported in 2009.^[4]

References

1. Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease, 2002
2. http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
3. Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT, 1999
4. Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical cancer research : an official journal of the American Association for Cancer Research 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.